MT-act
MT-act is a preclinical stage company that engineered MT-discover®, a proprietary platform to deliver first-in-class drugs for uncharted enzymes, to safely restore microtubule (MT) dysfunctions in chronic diseases. Unlike classic MT drugs, our first asset MT-X01 is an optimised safe small molecule targeting a novel mode of action to improve cardiac relaxation, without impairing contractility, under development to help patients suffering from hypertrophic cardiomyopathy.
Date, time and room information
May 6, 15:15 - 15:30, room Singapore
Category
Emerging biotech company
Title of the presentation
Innovative treatments to restore microtubule dysfunction safely in chronic diseases
Speaker information
| Name | Position | Institution |
|---|---|---|
| VAN DER LAAN | CEO |
Further information for the sponsor website
